Rational therapy for acute respiratory infections in young children with recombinant interferon alfa-2b

2020 ◽  
Vol 18 (3) ◽  
pp. 73-80
Author(s):  
E.V. Obraztsova ◽  
◽  
E.G. Golovacheva ◽  
L.V. Osidak ◽  
O.I. Afanasieva ◽  
...  
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Effective Means ◽  
Control Group ◽  
Interferon Α ◽  
Laboratory Studies ◽  
Recombinant Interferon ◽  
Age Related ◽  
Interferon Status ◽  
Respiratory Viral Infections

Influenza and acute respiratory viral infections (ARVI) remain a global health problem worldwide, and therefore the search for effective means of prevention and treatment of these diseases is extremely urgent. Objective. To evaluate the therapeutic efficacy and safety of a drug form of recombinant human IFN alpha-2b in combination with a complex of antioxidants (Viferon®-suppositories) in children with ARVI. Patients and methods. Clinical and laboratory studies were conducted in 100 children (toddlers up to 3 years old), hospitalized in St. Olga's children hospital No 4 with a diagnosis of influenza or ARVI. The etiology of diseases was established using serological methods and immunofluorescence analysis; the immune and interferon status was determined. VIFERON®-suppositories were used rectally daily in age-related dosages. The effectiveness of therapy was evaluated by comparative analysis of disease symptoms, as well as laboratory indicators – immune and interferon status. Results. The use of VIFERON® – suppositories contributed to reducing intoxication and catarrhal symptoms, speeding up the recovery time of patients. After the treatment, the children's ability to produce IFN-α and – γ, as well, as sIgA content in nasal secretions, increased, but there was no marked enhancement in serum IL-1β, IL-8 levels, whereas the children in the control group and in 30% of cases occurred to change them. The use of the medicine did not cause any complaints in patients and staff. Conclusion. Data from clinical and laboratory studies of children hospitalized for ARVI, whose therapy included the VIFERON® – suppositories, indicate a significant therapeutic effect of this medicine and restoration of the immune and interferon defense systems of patients. Keywords: children, acute respiratory viral infections, recombinant interferon α-2b, immune status, interferon status, antiviral therapy, cytokines IL-1β, IL-8, IL-10, TNF-α

Recombinant interferon α-2b (Grippferon) in the treatment and prevention of acute respiratory viral infections

Pharmateca ◽  
2020 ◽  
Vol 1_2020 ◽  
pp. 80-91
Author(s):  
L.V. Osidak Osidak ◽  
O.I. Afanasyeva Afanasyeva ◽  
E.G. Golovacheva Golovacheva ◽  
V.V. Gonchar Gonchar ◽  
M.M. Pisareva Pisareva ◽  
...  
Keyword(s):  
Viral Infections ◽  
Interferon Α ◽  
Recombinant Interferon ◽  
Treatment And Prevention ◽  
Respiratory Viral Infections

scholarly journals The effectiveness of the use of the drug recombinant interferon alfa-2b for the prevention of acute respiratory infections in preschool children

2019 ◽  
Vol 18 (4) ◽  
pp. 25-31
Author(s):  
S. A. Drakina ◽  
N. K. Perevoschikova ◽  
I. A. Seliverstov
Keyword(s):  
Preschool Children ◽  
Respiratory Infections ◽  
Main Group ◽  
Interferon Α ◽  
Acute Respiratory Infections ◽  
Perinatal Factors ◽  
Recombinant Interferon ◽  
Age Related ◽  
Epidemic Period ◽  
Ifn Γ

Acute respiratory infections (ARI) are the most common diseases of children, the main reasons for which are the age-related characteristics of the immune response, exacerbated by adverse perinatal factors, allergies, and increased contact with potential pathogens (the beginning of visits to preschool institutions, etc.).Objective: to evaluate the effectiveness of the use of the drug recombinant interferon α-2b to reduce the incidence of acute respiratory infections in preschool children.Throughout the year, there were 50 children under observation (average age 29.2 ± 0.97 months) attending preschool institutions. Recombinant interferon α-2b, ointment — VIFERON® 2500 IU 2 times a day for 14 days, in the next 4 weeks — 2500 IU 2 times a day 3 times a week was used for 25 children of the main group for the prevention of ARI in the pre-epidemic period.Results: The use of recombinant interferon α-2b in children of the main group showed a statistically significant decrease in the incidence of ARI, pneumonia, otitis, and the disappearance of pathological symptoms in the nasopharynx. An increase in the level of antiviral cytokines (IFN-α, p = 0.0088, IFN-γ, p = 0.0014) and a decrease in the concentration of pro-inflammatory (IL-1β, p = 0.0072) were recorded. Carriage of S. aureus, S. epidermidis, Candida albicans decreased by 2 times. Decrease in titer of antibodies to Str. pyogenes (p = 0.0251), Str. pneumoniae (p = 0.0491), Branchamella catarrhalis (p = 0.0369), Haemophilus influenzae (p = 0.0251) indicates a decrease in the sensitization of the child's organism to microbial antigens.

scholarly journals STATE OF IMMUNITY IN PRESCHOOLERS WITH ACUTE RESPIRATORY VIRAL INFECTIONS ASSOCIATED WITH ADENOID VEGETATIONS

2021 ◽  
Vol 65 (2) ◽  
Author(s):  
Evgeniia Dmitrova ◽  
◽  
Oleksandr Smiyan ◽  
Viktoria Holubnycha ◽  
Kateryna Smiian ◽  
...  
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Age Groups ◽  
Statistical Processing ◽  
Control Group ◽  
Healthy Children ◽  
Acute Period ◽  
Study Results ◽  
Respiratory Viral Infections ◽  
Acute Respiratory Viral Infection

Introduction. Acute respiratory infections are the most common infectious diseases worldwide among children of different age groups. Materials and methods. 59 children between the ages of 3 and 7 participated in the study. The first group included 22 patients with an acute respiratory viral infection, the second one consisted of 23 patients with acute respiratory viral infections associated with adenoid vegetation, and 14 apparently healthy children were included in the control group. Immunology research was conducted during the acute period of the disease. Statistical processing of received data was done with the standard statistical software EZR 1.41. Results. After the research, most of the patients with acute respiratory viral infections were identified an actual increase in CD3+, CD4+, CD8+, CD22+- cells and IgA, IgM in the blood serum. Simultaneously, in patients with acute respiratory viral infections associated with adenoid vegetation during the acute period, the increase in total lymphocytes was identified due to CD4+, CD8+, CD22+ cells and IgG. A comparative analysis of the study results of both groups of patients showed that children from the second group had a significantly higher level of CD3+- cells, while the CD22+- lymphocytes, IgA, IgM and IgG were significantly lower from the similar indicators of the first group. Conclusions. The acute period of the disease in children with acute respiratory viral infections, associated with adenoid vegetation, had an imbalance in both the cell and the immune system's humoral component

Prevention and treatment of Acute Respiratory Viral Infections in patients with first-time tuberculosis

2020 ◽  
Vol 18 (3) ◽  
pp. 167-177
Author(s):  
A.V. Mordyk ◽  
◽  
N.V. Bagisheva ◽  
D.I. Trukhan ◽  
M.V. Moiseeva ◽  
...  
Keyword(s):  
Viral Infections ◽  
Practical Interest ◽  
Tuberculosis Patient ◽  
Main Group ◽  
Control Group ◽  
Recombinant Interferon ◽  
Study Results ◽  
Prevention And Treatment ◽  
Respiratory Viral Infections ◽  
First Time

A tuberculosis patient with bacterial discharge requires a long-term inpatient treatment. During this time he/she may have several episodes of acute respiratory viral infections (ARVI). It is of scientific and practical interest to develop approaches to the treatment and prevention of ARVI in patients with first-time tuberculosis (TB). Objective: To assess the efficacy and safety of the recombinant interferon-based medication Grippferon® with loratadine (nasal ointment) for prevention and treatment of acute respiratory viral infections (ARVI) in patients with first-time tuberculosis. Patients and methods: A comparative, prospective, open study was conducted which included two stages. During the first stage two groups of patients with the first-time tuberculosis were compared: 25 patients in each group. Main group patients received the medication Grippferon® with loratadine for the treatment of ARVI. The second stage included two groups of patients with first-time tuberculosis: 100 patients in each group. Main group patients received the medication Grippferon® with loratadine for the prevention of ARVI. Results and conclusion: Based on our study results, we can conclude that the use of the medication Grippferon® with loratadine in the complex treatment of ARVI improved the therapy efficacy, reduced the severity and duration of the respiratory disease symptoms, while maintaining normal quality of life. We observed that main group patients, who received Grippferon® with loratadine for the ARVI prevention (seven days course), were less likely to develop ARVI, than control group ones (12% vs. 35%; χ2 = 9.19, p = 0.002), and the disease itself was shorter and milder. Keywords: ARVI, treatment, prevention, Grippferon with loratadine, patients with first-time tuberculosis

scholarly journals Neutrophils in respiratory viral infections

2021 ◽  
Author(s):  
Cecilia Johansson ◽  
Freja C. M. Kirsebom
Keyword(s):  
Viral Infections ◽  
Immune Cell ◽  
Respiratory Infections ◽  
Fungal Infections ◽  
Severe Disease ◽  
The Elderly ◽  
Viral Control ◽  
Immunological Mechanisms ◽  
Respiratory Viral Infections ◽  
Viral Respiratory Infections

AbstractViral respiratory infections are a common cause of severe disease, especially in infants, people who are immunocompromised, and in the elderly. Neutrophils, an important innate immune cell, infiltrate the lungs rapidly after an inflammatory insult. The most well-characterized effector mechanisms by which neutrophils contribute to host defense are largely extracellular and the involvement of neutrophils in protection from numerous bacterial and fungal infections is well established. However, the role of neutrophils in responses to viruses, which replicate intracellularly, has been less studied. It remains unclear whether and, by which underlying immunological mechanisms, neutrophils contribute to viral control or confer protection against an intracellular pathogen. Furthermore, neutrophils need to be tightly regulated to avoid bystander damage to host tissues. This is especially relevant in the lung where damage to delicate alveolar structures can compromise gas exchange with life-threatening consequences. It is inherently less clear how neutrophils can contribute to host immunity to viruses without causing immunopathology and/or exacerbating disease severity. In this review, we summarize and discuss the current understanding of how neutrophils in the lung direct immune responses to viruses, control viral replication and spread, and cause pathology during respiratory viral infections.

Effectiveness of protected aminopenicillins in treatment of non-social pneumonia in children

2021 ◽  
Author(s):  
Е.Е. Краснова ◽  
В.В. Чемоданов ◽  
Е.Г. Кузнецова
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Acquired Resistance ◽  
Age Groups ◽  
Clinical Manifestations ◽  
Severe Pneumonia ◽  
Physical Symptoms ◽  
Community Acquired Pneumonia ◽  
Natural Activity ◽  
Respiratory Viral Infections

Пневмония – острое инфекционно-воспалительное заболевание легких преимущественно бактериальной этиологии, характеризующееся выраженной в разной степени дыхательной недостаточностью, токсическими и респираторными нарушениями, локальными физикальными симптомами, а также инфильтративными изменениями на рентгенограмме. Заболеваемость внебольничными пневмониями повышается в октябре-декабре, достигая максимума в январе-апреле, коррелируя с сезонным повышением уровня острых респираторных вирусных инфекций. Схожесть симптомов дебюта пневмонии с проявлениями острых респираторных вирусных инфекций может привести к несвоевременной ее диагностике и, как следствие, к отсроченному началу лечения. Поэтому в период сезонной заболеваемости респираторными инфекциями должна повышаться настороженность врачей-педиатров в отношении внебольничной пневмонии. Антибактериальная терапия оказывает решающее влияние на прогноз пневмонии, поэтому при достоверном диагнозе или у больного в тяжелом состоянии с вероятным диагнозом ее следует начать незамедлительно. Выбор антибиотика в каждом случае внебольничной пневмонии проводят индивидуально с учетом природной активности препаратов в отношении предполагаемого возбудителя и их возможной приобретенной резистентности, тяжести и течения заболевания, наличия у пациента противопоказаний к использованию тех или иных антибиотиков. В статье приводятся сведения о диагностических критериях внебольничных пневмоний. Рассмотрены вопросы антибактериального лечения типичной нетяжелой пневмонии у детей разных возрастных групп амоксициллином с клавулановой кислотой и показана его эффективность. Результаты проведенного исследования позволяют заключить, что пероральное использование одного курса защищенного аминопенициллина эффективно при лечении типичной внебольничной нетяжелой пневмонии у детей разного возраста, о чем свидетельствует ликвидация основных клинических проявлений болезни в короткие сроки. Pneumonia is an acute infectious and inflammatory lung disease of predominantly bacterial etiology, characterized by respiratory failure, toxic and respiratory disorders, local physical symptoms, and infiltrative changes on the roentgenogram. The incidence of community-acquired pneumonia increases in October-December, reaching a maximum in January-April, correlating with the seasonal increase in the level of acute respiratory viral infections. The similarity of the symptoms of the onset of pneumonia with the manifestations of acute respiratory viral infections can lead to its untimely diagnosis and, as a consequence, to a delayed start of treatment. Therefore, during the period of seasonal morbidity with respiratory infections, the alertness of pediatricians in relation to community-acquired pneumonia should increase. Antibiotic therapy has a decisive influence on the prognosis of pneumonia, therefore, with a reliable diagnosis or in a patient in serious condition with a probable diagnosis, it should be started immediately. The choice of antibiotic in each case of community-acquired pneumonia is carried out individually, taking into account the natural activity of the drugs in relation to the alleged pathogen and their possible acquired resistance, the severity and course of the disease, the patient's contraindications to the use of certain antibiotics. The article provides information on the diagnostic criteria for community-acquired pneumonia. The issues of antibacterial treatment of typical non-severe pneumonia in children of different age groups with amoxicillin with clavulanic acid are considered and its effectiveness is shown. The results of the study allow us to conclude that the oral use of one course of protected aminopenicillin is effective in the treatment of typical community-acquired non-severe pneumonia in children of different ages, as evidenced by the elimination of the main clinical manifestations of the disease in a short time.

Indicators of the kinin blood system in severe forms of acute respiratory viral infections in children

1982 ◽  
Vol 63 (2) ◽  
pp. 51-52
Author(s):  
V. A. Anokhin ◽  
A. D. Tsaregorodtsev
Keyword(s):  
Viral Infection ◽  
Viral Infections ◽  
Severe Form ◽  
Blood System ◽  
Control Group ◽  
Healthy Children ◽  
Respiratory Viral Infection ◽  
Respiratory Viral Infections ◽  
Acute Respiratory Viral Infection ◽  
Apparently Healthy

The aim of this work was to study the parameters of the components of the kinin blood system in children with severe forms of acute respiratory viral infections (ARVI) with neurotoxicosis syndrome. 55 children with ARVI (aged from 1 to 6 months - 14, from 6 months to 1 year - 18, from 1 to 3 years - 11, from 3 to 7 years - 12). 38 patients were admitted in the first three days of illness, 12 - on 4-5 days and 5 - at a later date. 30 children had a severe form of acute respiratory viral infection and 25 - moderate. Adenovirus infection was diagnosed in 14 patients, influenza - in 16, parainfluenza - in 7, MS-viral infection in 5, mixed viral infection - in 13. The control group consisted of 10 apparently healthy children.

scholarly journals Clinical-epidemiological peculiarities of acute respiratory infections in children from 3 to 12 years and evaluation of effectiveness of antivirus therapy

2019 ◽  
Vol 11 (3) ◽  
pp. 38-45
Author(s):  
S. A. Khmilevskaya ◽  
N. I. Zryachkin ◽  
V. E. Mikhailova
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Molecular Genetic ◽  
Respiratory Viruses ◽  
Acute Respiratory Infections ◽  
Age Group ◽  
Leading Role ◽  
Respiratory Viral Infections ◽  
Acute Respiratory Viral Infection ◽  
Tract Infections

The aim: to study the etiological structure of acute respiratory infections in children aged 3 to 12 hospitalized in the early stages of the disease in the department of respiratory infections of the children’s hospital, and to reveal the features of their clinical course and the timing of DNA / RNA elimination of respiratory viruses from nasal secretions, depending on the method of therapy. Materials and methods: 100 children with acute respiratory infections aged 3 to 12 years were monitored. The nasal secrets on the DNA / RNA of respiratory viruses were studied by PCR. Depending on the method of therapy, patients were divided into 2 groups: patients of group 1 (comparison) received basic treatment (without the use of antiviral drugs), in patients of the 2nd group (main), along with basal therapy, the drug was used umifenovir in a 5-day course at the ageappropriate dosage. Results: In the etiologic structure of ARVI in children from 3 to 12 years, the leading place was taken by rhinovirus, influenza and metapneumovirus infections (isolated – 18%, 19% and 20% respectively, in the form of a mixed infection – 11%). The main syndromic diagnosis at the height of the disease was rhinopharyngitis. Complications were observed in 42% of cases, as often as possible with flu – 53% of cases. Features of metapneumovirus infection in children of this age group were: predominance of non-severe forms of the disease in the form of acute fever with symptoms of rhinopharyngitis, as well as a small incidence of lower respiratory tract infections. The use of the drug umiphenovir in children with acute respiratory viral infections of various etiologies contributed to significantly faster elimination of viral DNA / RNA from the nasal secretion, which was accompanied by a ecrease in the duration of the main clinical and hematological symptoms of the disease, a decrease in the incidence of complications, and reduced the duration of stay in hospital. Conclusion: application of modern molecular genetic methods of diagnostics made it possible to identify the leading role of influenza, metapneumovirus and rhinovirus infections in the etiology of acute respiratory viral infection in patients aged 3 to 12 years, and to determine a number of clinical features characteristic of this age group. The results of the study testify to the effectiveness of umiphenovir in the treatment of children with acute respiratory viral infections of various etiologies and allow us to recommend this drug as an effective and safe etiotropic agent.

scholarly journals The local interferon-corrective therapy in children with congenital cleft lip and palate, suffering from the recurrent respiratory infections

2020 ◽  
Vol 10 (2) ◽  
pp. 368-374
Author(s):  
I. V. Nesterova ◽  
M. N. Mitropanova ◽  
G. A. Chudilova ◽  
S. V. Kovaleva ◽  
E. O. Khalturina
Keyword(s):  
Oral Fluid ◽  
Cleft Lip ◽  
Cleft Lip And Palate ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Control Group ◽  
Recurrent Respiratory Infections ◽  
Congenital Cleft ◽  
Group 2 ◽  
Group 1

It is known that children with congenital cleft lip and palate are suffering from recurrent respiratory infections, which worsen the state of their health, and also complicate the results of reconstructive surgical treatment. The aim of the study was to detect defects of mucosal immunity in children with congenital cleft lip and palate, suffering from recurrent respiratory infections, and to create the program of local interferon corrective therapy with an assessment of its effectiveness. The studies included 56 children from the age of 1 to 3 years. Three groups of children were formed: group 1 – 26 children with congenital cleft lip and palate (antibiotic therapy); group 2 — 30 children with congenital cleft lip and palate (antibiotic therapy + local interferon therapy), group 3 — the control group. The clinical examination included a medical history, an assessment of the symptoms of recurrent episodes of acute respiratory infections and exacerbations of chronic infections. Microbiological studies were performed using standard methods. The status of local immunity was detected: the concentrations of secretory IgA, cytokines IL-17, IL-4, IL-6, IL-1β, IFNγ in the oral fluid were tested by ELISA. Results of the study established that in group 1 and group 2 clinical criteria of immunodeficiency with an infectious syndrome were revealed: repeated acute respiratory viral infections from 10 or more times a year, complicated by frequent exacerbations of chronic bacterial infection (up to 10 or more per year). Assessment of the state of local immunity in children with congenital cleft lip and palate revealed a lack of sIgA compared with the control group. Before treatment in group 2 oral fluid level of IL-17, IL-6 were statistically significant increase (p < 0.05); the results of the study also established increase in the level of IL-1β and a decrease in anti-inflammatory IL-4 and regulatory IFNγ relative to the control group (p > 0.05). After complex treatment with the inclusion of local interferon therapy in group 2 the appearance of sIgA, increase in the concentration of IL-4, IL-1β and a decrease IL-17 in oral fluid were observed (p > 0.05). The concentrations of IL-6, IFNγ did not change (p > 0.05). After treatment in group 2 there were a decrease in exacerbations of chronic upper respiratory tract infection and in frequency of acute respiratory viral infections compared with group 1 (p < 0.05). Positive clinical efficacy of local interferon therapy (the gel of recombinant IFNα2b in combination with oxidants — Viferon gel) in the process of staged rehabilitation of children with congenital cleft lip and palate has a protective clinical effect in reducing the frequency of acute respiratory viral infections, reducing the number of postoperative complications, reducing hospital stay, duration of antibacterial therapy and the number of exacerbations of chronic bacterial infection.

scholarly journals Evaluation of the effectiveness of ARVI treatment regimen including etiotropic (enisamium iodide) and symptomatic treatment

2020 ◽  
Vol 92 (3) ◽  
pp. 50-55
Author(s):  
D. A. Lioznov ◽  
E. J. Karnaukhova ◽  
T. G. Zubkova ◽  
E. V. Shakhlanskaya
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Clinical Symptoms ◽  
Randomized Study ◽  
Antiviral Drug ◽  
Main Group ◽  
Average Score ◽  
Control Group ◽  
Symptomatic Therapy ◽  
Respiratory Viral Infections

Aim. To assess the effectiveness of the use of the antiviral drug enisamium iodide in the complex treatment of acute respiratory viral infections (ARVI) caused by various pathogens in routine clinical practice. Materials and methods. А prospective randomized study included 134 patients who were treated in the epidemic season of influenza and ARVI in 20182019. All patients were examined for the presence of influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, parainfluenza virus, coronaviruses, rhinoviruses, adenoviruses in nasopharyngeal swabs by PCR. Patients of the main group received enisamium iodide along with symptomatic therapy, the control group received only symptomatic therapy. The primary parameter of the effectiveness of therapy was evaluated on the scale of the general severity of the manifestations of ARVI (Total Symptom Score TSS) from the 2nd to the 4th day and by the secondary criteria of effectiveness: assessment of the duration of ARVI, the severity of fever, the proportion of patients with normal body temperature, the duration of the main clinical symptoms of acute respiratory viral infections, the proportion of patients in whom complications requiring antibiotics were noted, the dynamics of interferon status on the 6th day. To conduct a statistical analysis, depending on the efficiency parameter, the ANCOVA method with a fixed group factor and an initial score on the TSS severity scale was used as covariates, a criterion for comparing quantitative indicators in two independent groups. Results. According to the results of the analysis of the primary efficacy parameter, the median (interquartile range) of the average score on the scale of the general severity of ARVI manifestations in the main group was 4.33 (3.675.83), in the comparison group 6.00 (4.677.25; p0.001). The duration of systemic and local manifestations of acute respiratory viral infections was statistically significantly less in the main group (p=0.002 and p=0.019, respectively). Prescription of additional therapy was required in 2 (2.9%) patients of the main group (patients taking enisamium iodide), compared with 8 (11.9%) patients in the control group. Serum levels of interferon  and interferon  on the last day of treatment were statistically significantly higher in patients of the main group compared with the control group (p0.001). Treatment (excellent) was evaluated by 42 (62.7%) patients, while in the control group only 17 (25.8%) patients gave similar ratings. Both patients (p0.001) and doctors (p0.002) rated therapy tolerance better in the study group. Conclusion. The results confirmed the safety and effectiveness of enisamium iodide as a treatment for ARVI and influenza. The antiviral, interferonogenic and anti-inflammatory properties of the drug are involved in the formation of an antiviral response and reduce the risk of complications, which makes it possible to reduce the number of symptomatic agents used.

Sign in / Sign up

Export Citation Format

Share Document